Greg Parekh, PhD
Board Chairman

Nayan Gregory Parekh, PhD, Chairman of the Board, is a founding partner at New Rhein Healthcare Investors LLC/BVBA. He serves as Chairman of the Board of Softhale Sprl, a respiratory drug device platform company; is a board member of CancerLinQ LLC, focused on big data and health informatics; and is a senior advisor to the American Society of Clinical Oncology (ASCO). From 2011 to 2013, Dr. Parekh was Chief Executive Officer of Biocartis SA focused on oncology molecular diagnostics. Previously, Dr. Parekh was the worldwide head of M&A at Novartis, where he was the chief integration manager for the Alcon/Novartis merger and a member of the Novartis Group Finance Committee. At Novartis, Dr. Parekh led the execution of over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, he spent 10 years in pharmaceuticals and biotechnology investment banking including Managing Director and Head of the European Healthcare Group for Deutsche Bank AG based in London and Vice President in the Therapeutics Group for JP Morgan in New York. He holds a PhD in Economics from Northwestern University.

Thomas N. Chase, MD

Thomas N. Chase, MD, co-founder of Chase Pharmaceuticals and Chief Scientific Officer, served as the company’s first President and Chief Executive Officer. He is a globally recognized thought leader in neurodegenerative disorders and their treatment, with a focus on the pathogenesis and treatment of Alzheimer’s disease, Parkinson’s disease and related disorders. Dr. Chase is the former Scientific Director and head of the Experimental Therapeutics Branch for the National Institute of Neurological Disorders and Stroke (NINDS). He received his MD from Yale University School of Medicine. Dr. Chase completed his neurology residency at Harvard Medical School and Mass General Hospital and his postdoctoral training in basic and clinical neuropharmacology at the National Institute of Mental Health. He has served as principal investigator on nearly 200 clinical trials, authored numerous patents and published over 500 peer-reviewed papers. Dr. Chase was the founding president of the American Society for Experimental NeuroTherapeutics (ASENT).

Stephen Cunningham, MD

Stephen Cunningham, MD, is a 25-year pharmaceutical veteran who has led teams that have developed, obtained regulatory approvals for, and launched numerous significant pharmaceuticals. He has global experience leading cross-functional teams from Phase 1 through life cycle management in the areas of Neuroscience, Cardiovascular, Metabolism, Respiratory, Immunology, Oncology, Women’s Health, Transplant and Clinical Pharmacology. During his career, Dr. Cunningham led and developed diverse cross-functional teams in Europe, Japan, Asia, Canada and the United States, and has broad experience in setting strategic direction, delivering projects, restructuring organizations and implementing transformational organizational change. Dr. Cunningham began his career at ICI Pharmaceuticals, holding global positions of increasing responsibility at ICI, Zeneca and lastly Novartis. After joining Novartis as Head of Medical Affairs in the US, Dr. Cunningham quickly assumed the role of Chief Scientific Officer and Head of US Clinical Development, Medical Affairs and Evidence-Based Medicine. While at Novartis he built a world class Novartis US Clinical Development and Medical Affairs organization supporting drug development, launch and life cycle management of products worldwide. Dr. Cunningham earned his MB, BCh, BAO and MD in Cardiology from Queen's University in Belfast.

Douglas S. Ingram, JD

Douglas S. Ingram, Chief Executive Officer, brings 20 years of biotech, pharmaceutical and medical device leadership to Chase. Most recently and until its acquisition by Actavis in early 2015, he was President of Allergan, a global pharmaceutical company with franchises in Neuroscience, Urology, Ophthalmology and Medical Aesthetics. Previously, Mr. Ingram was President of Allergan’s operations in Europe, the Middle East, and Africa. Earlier at Allergan he was responsible for building and leading numerous aspects of the global organization including Legal Affairs, Regulatory Affairs and Pharmacovigilance, Information Technology, Public Relations and External Communication, Human Resources, and Audit and Compliance. In addition to Chase Pharmaceuticals, Mr. Ingram is a board member of Endo International plc, Pacific Life Insurance Company and Nemus Biosciences. He is also the co-founder and limited liability partner of the OC Marathon. Mr. Ingram received his Bachelor of Science Degree, Magna Cum Laude, from Arizona State University, in 1985 and his Juris Doctorate, Summa Cum Laude and Order of the Coif, from the James E. Rogers College of Law, University of Arizona in 1988.

Karoly Nikolich, PhD

Karoly Nikolich, PhD, Chief Executive Officer and Chairman of the Board of Alkahest, has 30 years of biotechnology industry experience and is an expert in central nervous system therapeutics. Alkahest is focused on developing therapies derived from blood and its components to improve vitality and function into old age and on the diseases of aging, with an emphasis on cognitive dysfunction and dementia. Dr. Nikolich led Genentech’s entry into neuroscience during the 1980s and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, and co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Circuit Therapeutics and Alkahest. He has served on the boards and scientific advisory boards at a number of neurotherapeutics and biotechnology companies, as well as investment funds. Dr. Nikolich received his PhD in Biochemistry from Eotvos University in Budapest and was a postdoctoral fellow in Neuroscience at Tulane University and the University of California, San Francisco, before joining Genentech. He has been Consulting Professor in the Department of Psychiatry at Stanford University Medical School.

John M. Reher

John M. Reher, Managing Director of Brain Trust Accelerator Fund, LP, created the Brain Trust Accelerator Fund in 2006 with the goal of creating and investing in early-stage health care companies addressing brain-related diseases. Investments include Amnestix (sold to Sygnis Pharma), Neurofluidics (sold to Minnetronix), Satoris, Brainscope and Chase Pharmaceuticals. Earlier, Mr. Reher was founding President and Executive Director of Accelerate Brain Cancer Cure, Inc., a non-profit organization dedicated to accelerating therapies for treatment of brain cancer by employing venture principles to a philanthropic endeavor. Previously, Mr. Reher spent more than 12 years in venture capital as a general partner and co-founder of Medicus Venture Partners, an early-stage healthcare venture partnership with investments including Biosite Diagnostics, Inhale Therapeutic Systems (now Nektar), Tularik, and other successful companies. He began his career in the pharmaceutical industry at G.D. Searle Pharmaceuticals and later held marketing, licensing, acquisitions and overall team leader positions at Genentech. Mr. Reher received a Masters of Management degree from Northwestern University.

Vikram Sudarsan, PhD

Vikram Sudarsan, PhD, heads Cipla Pharmaceuticals innovation agenda via biotech venture investments, drug development and portfolio strategy. He specializes in global biotech product development, valuation, clinical strategy, commercial analysis, and conducting various types of sell-side and buy-side transactions including venture finance, acquisitions, capital raises and licensing deals. Dr. Sudarsan has experience across several therapeutic modalities including small molecules, antibody therapies and cell therapies, and across numerous therapeutic areas including neuroscience, oncology, infectious diseases and metabolic diseases. He has expertise in pricing, market access and health economics. Prior to Cipla, Dr. Sudarsan worked in healthcare investment banking, helped found IMS Health Capital, and held consulting roles at IMS Consulting Group and PriceSpective, LLC before its sale to Icon PLC. Dr. Sudarsan has consulted for government entities in the United States and advised on personalized medicine, RNAi, drug delivery and viral genetics. He serves on the board of Stempeutics Ltd. Dr. Sudarsan conducted graduate studies at Cambridge University, UK, received his PhD in Genetics and Developmental Biology from the University of Sheffield, UK, and carried out postdoctoral research at Stanford University/Howard Hughes Medical Institute.

Raphaël Wisniewski

Raphaël Wisniewski, a partner in Edmond de Rothschild Investment Partners, has participated in more than 20 investments in European or American companies in biotechnology, medical technologies and molecular diagnosis. He began his career in London, where he spent seven years in the healthcare and investment banking industries. He was initially part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions. He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney and Goldman Sachs. He currently sits on the boards of Axonics Modulation Technologies, Cellnovo Group, Genticel, Implanet SA, Poxel SA, and ReViral. Mr. Wisniewski graduated from the French Business School HEC and received a Master’s in Applied Economics from Institut d'Etudes Politiques.